US EditionUS FDA issues EIR for Lupin’s injectable facility in Nagpur - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
US FDA issues EIR for Lupin’s injectable facility in Nagpur - Express Pharma
Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable manufacturing facility in Nagpur, India. The report pertains specifically to the company’s drug-medical device combination products. The EIR follows an inspection of the facility carried out by the US FDA between 10 and 13 June 2024. Commenting on the development, Nilesh Gupta, Managin…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
